文献速递慢性肾脏病肾血管病与高血压血液净化与透析

慢性肾脏病传统心血管危险因素管理:证据总结

Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
PubMed 文献 · Am J Kidney Dis · 2018-02-23

非透析依赖的慢性肾脏病患者死于心血管疾病的风险是普通人群的10倍,透析患者风险更高,但这些患者常被排除在传统心血管危险因素干预研究之外。本文综述了高血压、肾素-血管紧张素-醛固酮阻断、阿司匹林、降脂、血糖控制及生活方式干预在慢性肾脏病患者中的现有证据和指南推荐,并指出知识缺口。

要点

  • 非透析依赖慢性肾脏病患者心血管死亡风险是普通人群10倍,透析患者更高。
  • 降脂治疗改善非透析依赖患者心血管结局,但对透析患者无获益。
  • 严格血糖控制对无白蛋白尿者有益,但对白蛋白排泄>300mg/g者无获益,透析患者无数据。

核心结论

  • 非透析依赖慢性肾脏病患者心血管死亡风险是普通人群10倍,透析患者风险更高,但传统危险因素干预证据有限。

研究设计与样本

  • 这是一篇综述,总结了慢性肾脏病患者传统心血管危险因素干预的现有最佳证据和当前临床指南。

主要发现

  • 高血压治疗对慢性肾脏病有益,但最佳目标血压尚未确定。
  • 肾素-血管紧张素-醛固酮阻断可能预防慢性肾脏病患者心血管事件。
  • 非透析依赖慢性肾脏病患者中阿司匹林风险可能等于获益,透析患者无试验数据。
  • 降脂治疗改善非透析依赖患者心血管结局,但不改善透析患者结局。
  • 严格血糖控制预防无白蛋白尿者心血管事件,但对基线白蛋白排泄>300mg/g者无获益,透析患者无数据。

关键数值与推荐

  • 非透析依赖慢性肾脏病患者心血管死亡风险为普通人群10倍。
  • 基线白蛋白排泄>300mg/g者严格血糖控制无心血管获益。

临床怎么用

  • 应基于现有证据管理慢性肾脏病患者传统心血管危险因素,同时认识证据缺口。

局限性

  • 生活方式干预数据多为观察性研究并从非慢性肾脏病人群外推。
  • 慢性肾脏病患者常被排除在传统心血管危险因素干预研究之外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) are 10 times more likely to die of cardiovascular (CV) diseases than the general population, and dialysis-dependent patients are at even higher risk. Although traditional CV risk factors are highly prevalent in individuals with CKD, these patients were often excluded from studies targeting modification of these risks. Although treatment of hypertension is beneficial in CKD, the best target blood pressure has not been established. Trial data showed that renin-angiotensin-aldosterone blockade may prevent CV events in patients with CKD. The risks of aspirin may equal the benefits in NDD-CKD samples, and there are no trials testing aspirin in dialysis-dependent patients. Lipid-lowering therapy improves CV outcomes in NDD-CKD, but not in dialysis-dependent patients. Strict glycemic control prevents CV events in nonalbuminuric individuals, but showed no benefit in those with baseline albuminuria with albumin excretion > 300mg/g, and there are no data in dialysis-dependent patients. Data for lifestyle modifications, such as weight loss, physical activity, and smoking cessation, are mostly observational and extrapolated from non-CKD samples. This comprehensive review summarizes the best existing evidence and current clinical guidelines for modification of traditional risk factors for the prevention of CV events in patients with CKD and identifies knowledge gaps.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Gregg LP, Hedayati SS. Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data? Am J Kidney Dis. 2018. PMID: 29478869. doi:10.1053/j.ajkd.2017.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。